ERBB2 and breast cancer: In the Herceptin Adjuvant (HERA) trial, women with HER2-positive advanced breast cancer were randomly assigned to 1 or 2 years of treatment with trastuzumab or observation after locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy [4].